DIABETES UK: Pravastatin Appears To Restore Endothelial Function In Type 1 Diabetes
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




DIABETES UK: Pravastatin Appears To Restore Endothelial Function In Type 1 Diabetes

By David Jack, M.D.

Special to DG News

GLASGOW, SCOTLAND -- April 5, 2001 -- Patients suffering from type 1 diabetes are at risk of developing atherosclerosis prematurely. The endothelial dysfunction is due to reduced bioavailability of endothelium-derived nitric oxide (NO) and this is a key factor in the pathogenesis of premature atherosclerosis.

Young adults with this form of diabetes exhibit impairment of flow-mediated dilatation and available evidence suggests that HMG-Co A reductase inhibitors (statins) can have beneficial effects on endothelial function.

A study presented at the Diabetes UK Annual Professional Meeting by Dr. K. Moore and colleagues of the Department of Surgery and Endocrinology, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland, showed the effects of a one-month treatment with pravastatin on flow-mediated-dilatation in eight young men (age 18-31) with type 1 diabetes (HbA1c 7.2 +/- 1.4 percent). Baseline data on eight age-matched controls was also obtained and flow-mediated dilation of the brachial artery was measured by high resolution ultrasonography. The increase in blood pressure was obtained by inflating a cuff on the distal forearm to a pressure of 240 mmHg for 4.5 minutes.

The mean flow-mediated dilatation in the diabetics rose from 4.5 percent pre-treatment to 8.44 percent post-treatment which is a highly significant increase ; the mean value in the control subjects was 7.98 percent.

This pilot study shows that a one-month treatment with pravastatin is able to reverse abnormal flow-mediated dilatation in young type 1 diabetics.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities